Navigation Links
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease
Date:6/18/2013

a poster entitled Randomized Trial of Extended Release Amantadine in Parkinson's Disease Patients with Levodopa-induced Dyskinesia (EASED Study) (abstract #443) at 12:30 pm AEST.

About the EASED™ Study

The EASED study was a randomized, double-blind, placebo-controlled clinical trial that enrolled 83 Parkinson's disease subjects at 31 study sites in the US (NCT 01397422). The study's primary efficacy analysis compared ADS-5102 to placebo for reduction in LID over eight weeks as assessed by the Unified Dyskinesia Rating Scale (UDysRS). Secondary efficacy outcome measures included changes in a standardized PD diary, including: ON time without troublesome dyskinesia; overall PD clinical status as assessed by the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS); and fatigue measured using the Fatigue Severity Scale. The EASED trial also included an assessment of dose response for ADS-5102. The study enrolled male and female subjects aged 30 to 85 years who had Parkinson's disease and were experiencing troublesome LID. Study participants were randomized to receive 260 mg, 340 mg, or 420 mg doses of ADS-5102 or placebo once-nightly for eight weeks with a two-week safety follow-up. In order to participate in the study, subjects had to have a score of at least 2 on Part IV, item 4.2 (functional impact of dyskinesia) of the MDS-UPDRS at screening and Day 1, and be experiencing at least two 30 minute intervals of ON time with troublesome dyskinesia between the hours of 9 am-4 pm. Safety measures included adverse events and routine safety laboratory tests that were reviewed during the study by an independent data monitoring committee.

About ADS-5102 (Nurelin™)

ADS-5102 is a proprietary, investigational, extended-release formulation of amantadine HCl in development for the treatment of central nervous system (CNS) disorders, including LID in Parkinson's disease. Designed for once-nightly administration, ADS-5102's unique "
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
2. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
3. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
4. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
5. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
6. Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
7. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
8. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Chronische Nierenerkrankung: Das Risiko des Fortschreitens reduzieren -- Prismic Pharmaceuticals sichert sich exklusive Lizenzrechte
10. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
11. Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HILL, Conn. , July 29, 2014 Numotion,s ... 2014, Mike Swinford will be the company,s new ... a highly successful 22-year career at GE where he worked ... million in annual revenue to over $5 billion. His most ... Global Services. "I am thrilled to join ...
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education ... for the science, technical, and medical communities, has announced ... first off-line mobile application of the world-renowned medical education ... new AccessMedicine App , available for download onto ... now be able to gain access to valuable ...
(Date:7/29/2014)... 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... its second quarter 2014 financial results after the Nasdaq ... then host a live conference call and webcast to ... Thursday morning, August 7, 2014 at 8:00 a.m. Eastern ... access the live conference call by dialing 866-952-1907 (US) ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... China, Dec. 16, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical ... the "Company"), a developer, manufacturer and distributor of botanical ... that Mr. David Dong was named the Company,s new ... Mr. Dong,s career spans over 10 years ...
... Dec. 16, 2010 WaferGen Biosystems, Inc. (OTC Bulletin ... state-of-the-art genomic analysis systems, and the Integrated BioBank of ... strategic relationship that will expand the use of the ... personalized medicine.   The agreement includes: ...
Cached Medicine Technology:China Botanic Appoints David Dong as New Chief Financial Officer 2China Botanic Appoints David Dong as New Chief Financial Officer 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5
(Date:7/29/2014)... Premier Women’s Health , a six-physician ... has affiliated with Allegheny Health Network’s renowned Women’s Health ... babies and perform surgical procedures at Heritage Valley Sewickley. ... referred to Allegheny Health Network’s West Penn Hospital ... West Penn Hospital and its highly regarded Women’s Health ...
(Date:7/29/2014)... IsoComforter, Inc ., one of ... today the introduction of the innovative new Iso-Hip Wrap. ... created for post operative hip replacement patients. The plush ... the benefits of cold therapy while resting, sitting, or ... replacements are done every year. Cold therapy is ...
(Date:7/29/2014)... According to the new market research report, ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... Banking & Finance), and Geography - Global Trends ... MarketsandMarkets, the global Fingerprint Sensors Market is projected ... a high CAGR of 16.8% from 2014 to ...
(Date:7/29/2014)... 29, 2014 Test instruments after ... and protein soils where it matters most – ... leading manufacturer of premium domestic appliances, introduces ProCare ... instruments are effectively cleaned. The ProCare liquid is ... immediately after processing. After 3 minutes, users visually ...
(Date:7/29/2014)... (CA) method is in principle suitable to find out ... widely use it in health economic evaluations, some (primarily ... the result of a pilot project by the German ... Following the Analytic Hierarchy Process (AHP), CA is the ... experts. , Summarize outcome-specific results to an overall ...
Breaking Medicine News(10 mins):Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:New IsoComforter Cold Therapy Unit Plus Hip Wrap Gives Post Operative Hip Replacement Patients Faster Recovery Times 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4
... Unhappy marriages are harmful to the self-esteem and health of ... to higher levels of psychological distress when compared to those ... as many as 1,150 people in unhappy // marriages ... of sociology, human development and family studies, and demography said ...
... the heart with the progress of age can be postponed by ... which the Journal of the American College of Cardiology has published. ... primary aging can // be delayed by restricting calories in human ... fact has already been proved in the case of small mammals. ...
... regard to the hormone replacement therapy (HRT), another research has put ... to the heart. //The risk of a coronary heart disease is ... the HRT at an younger age, when in comparison to women ... cardiovascular benefits to be seen in the case of women who ...
... Stetson have reported in the Journal Immunity that the host ... infection. // ,Viruses are classified based on their ... found that immune response which acts in recognisation of these ... RNA viruses. ,Immune response against the virus acts ...
... Professor Harvey Lodish and his post-doc Chengcheng Zhang from Whitehead ... of growth factors// which enriches and increases the number of ... into the recipient. ,Stem cell therapy as ... therapy is very high and it requires isolating large number ...
... Neurone Disease (MND), a fatal nerve disease could be improved ... ,Patients suffering from Motor Neurone Disease (MND) could ... works by helping people with MND who suffer from weakness ... reported. ,At present just one drug is licensed ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: